ASCO reports Phase 2 clinical trial of Lorlatinib suggests that Lorlatinib has robust intracranial activity in patients with CNS-only progression on second-generation ALK inhibitors. The study took place between Nov. 2016 and Jan. 2019. Twenty-three patients were enrolled.
Control of intracranial disease was observed in 21 (95%) evaluable patients @ 12 weeks.
Adverse effects included high cholesterol (96%) edema (65%) COGNITIVE effects (52%) and mood effects (43%). Also noted is Hypertriglycedenia.